

**Virginia Medicaid**  
**Pharmacy & Therapeutics Committee Meeting**  
Agenda  
600 East Broad Street – 1st Floor Conference Rooms  
Richmond, VA 23219  
Thursday, January 16, 2025 – 1 PM – 4 PM

**Welcome and Comments** **Cheryl J. Roberts, J.D. Medicaid Director**

**Call to Order** **Lisa Price Stevens, MD, Chief Medical Officer, Chair**

**Drug Utilization Review (DUR) Board Report** **Rachel Cain, PharmD**

**Approval of Minutes from October 8, 2024 Meeting** **P&T Committee Members**

**Old Business** **P&T Committee Members**

- **Bylaws**

**PDL (PREFERRED DRUG LIST) Management** **P&T Committee Members**

**PDL Off Cycle – New Drug Review (*Therapeutic Class*)**

**Brand Drugs**

- Livdelzi (Bile Salts)
- Neffy (Epinephrine, Self-Administered)

**PDL Off Cycle – New Generics (*Therapeutic Class*)**

- sacubitril-valsartan (Angiotensin Receptor Blockers)
- timolol (Glaucoma Agents, Beta Blockers)

**PDL Quarter 1 – Annual Review: Classes with updates**

**Blood Modifiers**

- Erythropoiesis Stimulating Proteins

**Central Nervous System**

- CNS Stimulants and Related Agents (Closed Class)
- Alzheimer's Agents (Cholinesterase Inhibitors & NMDA Receptor Antagonist)
- Multiple Sclerosis Agents (Closed Class)
- Neuropathic Pain

**Endocrine and Metabolic Agents**

- Hypoglycemics: Incretin-Mimetics (includes DPPIV & combination) (Closed Class)
- Hypoglycemics: Insulins
- Hypoglycemics: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (Closed Class)

**PDL Quarter 1 – Annual Review**

**Therapeutic Classes without Significant Updates (reviewed by the Department)**

**Blood Modifiers**

- Antihyperuricemics

**Central Nervous System**

- Skeletal Muscle Relaxants

- Smoking Cessation Agents

**Endocrine and Metabolic Agents**

- Androgenic Agents
- Bone Resorption Suppression and Related Agents (includes bisphosphonates, calcitonin and others)
- Estrogens (vaginal)
- Hypoglycemics: Alpha-Glucosidase Inhibitors
- Hypoglycemics: Meglitinides
- Hypoglycemics: Metformin
- Hypoglycemics: Sulfonylureas
- Hypoglycemics: Thiazolidinediones
- Pancreatic Enzymes
- Progestational Agent (Closed Class)

**Confidential Meeting (Pricing Information Discussion)**

**P&T Committee Members & DMAS Staff**

**Criteria Discussion of Off Cycle New Drugs**

**P&T Committee Members**

**Criteria Discussion of Quarter 1 Drugs**

**P&T Committee Members**

*\*Criteria discussions will be held for the above classes and drugs only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

**Criteria Discussion of Short-Acting and Long-Acting Opioids**

**P&T Committee Members**

**Other Business**

**Chair**

**Next Meeting – April 17, 2025 (tentative)**

**Chair**

**Oral Presentations:** The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on **only** the drug classes in Quarter 1 scheduled for review at the January meeting and new drugs in PDL OFF Cycle listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Quarter 1 Annual Reviews – January 2024 to present.
- Off Cycle New Drugs – January 2023 to present.

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. Speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation to verify the presentation is scheduled.**

**Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter.** Please send requested information to [pdlinput@dmavirginia.gov](mailto:pdlinput@dmavirginia.gov) and [david.damico@primetherapeutics.com](mailto:david.damico@primetherapeutics.com) by 5 p.m. EST on Thursday, December 19, 2024.

**Written information/comments:** The P&T Committee will also accept written comments for consideration. Please send statements to [pdlinput@dmavirginia.gov](mailto:pdlinput@dmavirginia.gov) by 5 p.m. EST Thursday, December 19, 2024.